The Diabetic Retinopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Retinopathy pipeline products will significantly revolutionize the Diabetic Retinopathy market dynamics.
Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a microvascular disorder occurring due to the long-term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. Diabetic retinopathy affects people with diagnosed or undiagnosed diabetes mellitus. The propensity to develop diabetic retinopathy is directly proportional to the age of the patient and duration of diabetes, as well as to poor glycemic control and fluctuating blood pressure level.
Some of the key facts of the Diabetic Retinopathy Market Report
- The Diabetic Retinopathy market size is estimated at USD 128,294 Million by 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to the American Academy of Ophthalmology, Diabetic retinopathy (DR) results from high blood sugar levels, which cause damage to blood vessels in the retina
- The total cases of Diabetic retinopathy worldwide was estimated at around 93 million cases
- The individual lifetime risk of DR is estimated to be 50–60% in patients with type 2 diabetes and over 90% in patients with type 1 diabetes
- Key Diabetic Retinopathy Companies: Genentech, Opthea Limited, Regenxbio, Kodiak Sciences Inc, AdverumBiotechnologies, and others
- Key Diabetic Retinopathy Therapies: OPT-302, RGX-314, KSI-301, Brolucizuma, ADVM-022, and others
- The Diabetic retinopathy epidemiology based on gender analyzed that the prevalence of Diabetic retinopathy is slightly higher in males as compared to females
Get a Free sample for the Diabetic Retinopathy Market Report
Key benefits of the Diabetic Retinopathy Market report:
- Diabetic Retinopathy market report covers a descriptive overview and comprehensive insight of the Diabetic Retinopathy Epidemiology and Diabetic Retinopathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Diabetic Retinopathy market report provides insights on the current and emerging therapies.
- Diabetic Retinopathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Diabetic Retinopathy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Diabetic Retinopathy market.
Discover more about therapies set to grab major Diabetic Retinopathy market share @ Diabetic Retinopathy market forecast
Diabetic Retinopathy Epidemiology Segmentation:
The Diabetic Retinopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Diabetic Retinopathy
- Prevalent Cases of Diabetic Retinopathy by severity
- Gender-specific Prevalence of Diabetic Retinopathy
- Diagnosed Cases of Episodic and Chronic Diabetic Retinopathy
Diabetic Retinopathy Market
The dynamics of the Diabetic Retinopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as RGX-314, KSI-301, and others during the forecasted period 2019-2032.
Download the report to understand which factors are driving Diabetic Retinopathy epidemiology trends @ Diabetic Retinopathy Epidemiological Insights
Emerging Diabetic Retinopathy Therapies & Key Companies
- OPT-302: Genentech
- RGX-314: Opthea Limited
- KSI-301: Regenxbio
- Brolucizuma: Kodiak Sciences Inc
- ADVM-022: AdverumBiotechnologies
Scope of the Diabetic Retinopathy Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Diabetic Retinopathy Companies: Genentech, Opthea Limited, Regenxbio, Kodiak Sciences Inc, AdverumBiotechnologies, and others
- Key Diabetic Retinopathy Therapies: OPT-302, RGX-314, KSI-301, Brolucizuma, ADVM-022, and others
- Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
- Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Diabetic Retinopathy Market Access and Reimbursement
Table of Contents
1. Diabetic Retinopathy Market Report Introduction
2. Executive Summary for Diabetic Retinopathy
3. SWOT analysis of Diabetic Retinopathy
4. Diabetic Retinopathy Patient Share (%) Overview at a Glance
5. Diabetic Retinopathy Market Overview at a Glance
6. Diabetic Retinopathy Disease Background and Overview
7. Diabetic Retinopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic Retinopathy
9. Diabetic Retinopathy Current Treatment and Medical Practices
10. Diabetic Retinopathy Unmet Needs
11. Diabetic Retinopathy Emerging Therapies
12. Diabetic Retinopathy Market Outlook
13. Country-Wise Diabetic Retinopathy Market Analysis (2019–2032)
14. Diabetic Retinopathy Market Access and Reimbursement of Therapies
15. Diabetic Retinopathy Market drivers
16. Diabetic Retinopathy Market barriers
17. Diabetic Retinopathy Appendix
18. Diabetic Retinopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Diabetic Retinopathy treatment, visit @ Diabetic Retinopathy Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/